Coenzyme Q10 (CoQ10) - Research Brief
|I Product Info||I Ingredients||I Recommended Use||I Clinical Trials||I Research Brief||I References|
Indication: cardiovascular disease prophylaxis, coronary circulation impairment, insufficient cardiac muscle nourishment, high blood pressure, muscle weakness, impaired metabolism, intensive sports training, physical overload.
Main Actions: heart muscle energizer, essential for healthy cardiovascular system, improves host defenses, strengthens cell membranes, maintains healthy gums, potent antioxidant.
Ingredients (per 1 gelcap):
Coenzyme Q10 (Ubidecarenone) – 50 мg, Conjugated Linolic Acid (CLA) – 400 mg, Flaxseed Oil (55% ALA (alpha linolic acid)) – 200 mg
Low USA domestic & international shipping
Coenzyme Q10 (CoQ10) Research Brief:
The new product by Santegra® is the most bioavailable form of CoQ10 on the market today. The positive effect of CoQ10 on the human body is well known, but its low bioavailability was a problem for a long time. The new unique methods were used in the manufacturing process that helps increase solubility and absorbency of coenzyme Q10.
The human double-blind, randomized clinical study showed that new CoQ10 had a peak absorption that was 808% higher and relative bioavailability that was 441% greater than that of standard dry CoQ10 powder.
The new CoQ10 AUC (0-28 day) was 53.31 ug/ml a day compared to 9.85 for the dry powder. (pic. 1)
36-hour peak absorption study showed that 7.89% of the 100 mg dose of the new CoQ10 was absorbed at Cmax and an estimated total absorption was 11.65% compared to 0.87% at Cmax and 1.34% estimated total absorption for the dry powder product standard. (pic. 2)
In a 28 day steady state bioavailability study, the basal steady state plasma CoQ10 levels were 3.46 ug/ml for the new CoQ10 compared to 1.35 ug/ml for the standard CoQ10 powder.
This means that much lower daily dose of CoQ10 is required to achieve an effective level.